|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1089 - 0.1089|
|52 Week Range||0.0750 - 0.3980|
|Beta (5Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 22, 2022 - Aug 26, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe. Khiron's growth aligns with its mission to improve consumers' quality of life through its global network of medical cannabis treatments clinics.
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announces the results of its 2022 Annual General and Special Meeting of shareholders (the "Meeting") held on June 23, 2022.
Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), is pleased to announce that it has closed today its previously announced underwritten overnight public offering of units of the Company ("Units"), including the exercise in full of the over- allotment option (the "Offering").